WANBURY.NSE · Wanbury Limited

-

Please sign in to comment on WANBURY.NSE

1 Comment

Admin

4 years ago

Wanbury Limited is currently in a long term uptrend where the price is trading 23.7% above its 200 day moving average.

From a valuation standpoint, the stock is 87.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.6.

Wanbury Limited's total revenue rose by 13.2% to $1B since the same quarter in the previous year.

Its net income has increased by 378.0% to $59M since the same quarter in the previous year.

Finally, its free cash flow fell by 157.6% to $-82M since the same quarter in the previous year.

Based on the above factors, Wanbury Limited gets an overall score of 4/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NSE
CurrencyCode	INR
ISIN	INE107F01022

Market Cap	9B
PE Ratio	21.66
Target Price	None
Beta	0.44
Dividend Yield	None

ABOUT

Wanbury Limited

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India and internationally. The company offers formulations for gynecology, orthopedics, hematinic, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas. The company was formerly known as Pearl Organics Limited and changed its name to Wanbury Limited in 2004. Wanbury Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.

WANBURY.NSE · Wanbury Limited

-

Wanbury Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Wanbury Limited using a moving average strategy